Cancer Control John Stoddard Cancer Center

UnityPoint Clinic Urgent Care - Altoona

Closed Patients
Waiting Now

UnityPoint Clinic Urgent Care - Ingersoll

Closed Patients
Waiting Now

Urgent Care - Ankeny

Closed Patients
Waiting Now

Urgent Care - Lakeview

Closed Patients
Waiting Now

Urgent Care - Merle Hay

Closed Patients
Waiting Now

Urgent Care - Southglen

Closed Patients
Waiting Now

Urgent Care - Urbandale

Closed Patients
Waiting Now

Gastrointestinal Research Studies

NEUROENDOCRINE TUMORS 

A021602: Randomized, double-blinded phase III study of cabozantinib versus placebo in patients with advanced neuroendocrine tumors after progression on everolimus  

BILIARY TRACT 

S1815: A Phase III Randomized Trial Of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed Advanced Biliary Tract Cancers  


COLORECTAL 

GI004: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer 


S1613: A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) with HER-2 Amplification  

COLON 

A021502: Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair  

ANAL 

EA2165: A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer 

RECTAL 

GI002: A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer 

HEPATOCELLULAR 

R1112: Randomized Phase III Study of Sorafenib Versus Sterotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma  

CANCER CONTROL 

S0820: A Double-Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES) 

CANCER CARE DELIVERY RESEARCH 

EAQ162CD: Longitudinal Assessment of Financial Burden in Patients with Colon or Rectal Cancer Treated with Curative Intent 

 S1415CD: "TrACER": Trial Assessing CSF prescribing Effectiveness and Risk